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Therapeutic Options for Localized Carcinoma ofthe Prostate:
The Role of External Beam Radiation Therapy

Mark S. Khil, MD,* and Jae Ho Kim, MD, PhD'

During the last three decades the use of ionizing radiation, hoth external heam radiotherapy and
interstitial radionuclide implant (hrachytherapy), has greatly increasedfor the treatment of cancer of
the prostate. The increased use of radiation therapy is in part due to the technological advance of
high-energy megavoltage units as well as the steadily improving long-term results of radiotherapy.
Because ofthe comparable tumor control rates, patients wdh early stage prostate cancer have several
therapeutic options for curative treatment including radical prostatectomy, external beam radiation
therapy, and interstitial hrachytherapy. The role of external heam radiotherapy is discussed in terms
ofthe primary management of early and locally advanced prostate cancers as well as the treatment
of residual or recurrent disease after prostatectomy. A new approach combines antimitotic chemotherapeutic agents and radiation therapy for the treatment of locally advanced cancers of the
prostate. (Henry Ford Hosp Med J 1992;40:103-7)

P

rostate cancer is the second most common malignant disease in American men, and the incidence increases each
decade after the age of 50. Approximately 122,000 new cases of
prostate cancer were expected to be diagnosed in 1991. A l though 60% of these patients will have localized disease, 32,000
deaths are predicted (1),
The use of ionizing radiation in the treatment of adenocarcinoma of the prostate, both by external beam (teletherapy) and by interstitial implant (hrachytherapy), has greatly increased during the last three decades. Of more than 200 patients
with cancer of the prostate seen annually in our departmenf over
50% are being evaluated for definitive radical radiation therapy
for localized disease. Our purpose is to review this treatment and
to emphasize the possibility of cure with extemal beam radiotherapy.

Historical Perspective
Reports of extemal beam radiation therapy from the 1930s
through the 1950s dealt mainly with results obtained with
orthovoltage (250 KVP) radiation (2,3). This treatment delivered maximum energy in the skin and subcutaneous tissues with
excessive scattering of radiation; the delivery of a tumoricidal
dose to the prostate was not always possible without unacceptable damage to the skin and sunounding normal tissue. Despite
these limitations. Smith and Pierson (4) and Widmann (5) reported relatively good results in the relief of pain associated
with bony metastases, and the latter presented impressive results
in 82 cases with advanced local neoplasm treated for palliation
of symptoms. A l l forms of treatment were eclipsed in 1941
when Huggins et al (6) showed that the growth of prostatic carcinoma could be retarded by androgen deprivation. Later, however, as the limitations of hormonal treatment became apparent,
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interest renewed in the radiotherapeutic management of the disease. In 1952, Flocks et al (7) at the University of Iowa showed
that the instillation of a short-lived radionuclide, gold colloidal
suspension (''^Au), directiy into the neoplasm and/or periprostatic soft tissues following subtotal resection decreased the
local recunence rate.
The use of ionizing radiation, stimulated by the report of
Flocks et al, and the development of a high-energy megavoltage
x-ray machine prompted renewed interest in die possible use of
extemal beam radiotherapy. The availability of new megavoltage radiation therapy units (> 1 MeV) allowed the delivery o f a
high tumoricidal dose to the prostate without excessive damage
to the adjacent normal tissues—skin, subcutaneous tissues, and
bones. In 1962 Bagshaw and Kaplan (8) at Stanford University
presented their observations on the application of extemal beam
inadiation as definitive treatment for carcinoma of the prostate.
This was followed in the next two decades by other reports
which attested to the radiocurabitity of carcinoma of the prostate
and the feasibility of definitive treatment by extemal beam megavoltage inadiation.

Therapeutic Options for Early
Stage Prostate Cancer
Although many urologic oncologists agree that patients with
locally advanced prostatic cancer (stages B2 and C) may be best
treated with definitive extemal beam radiation therapy, the use
of radiotherapy in the treatment of early stages of disease (i.e..
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Figure—Isodose distribution ofthe radiation dose, taken at the
level of the prostate (A, B, C, D represent an isodose line of
6,600 cGy, 6,400 cGy, 5,000 cGy. and 4,000 cGy, respectively).
A2 and B1) has been less well defined. Radical prostatectomy is
a well-established therapy for early localized prostate cancer. In
particular, patients with stage B l cancer with low-grade histology (eg,, Gleason score of less than 6) are the ideal group for
radical surgery, tf patients are not candidates for radical surgery
for either medical or other reasons, they are eligible for radical
radiation therapy. Such patients are then evaluated for either radioactive interstitial implant or extemal beam radiation therapy.
Radionuclide hrachytherapy offers several advantages over
extemal beam radiation therapy. These include 1) delivery of a
high local dose to the prostate over several months, 2) limited
injury to the adjacent organs because ofthe geometric fall-off of
the radiation dose with distance from the seeds as well as attenuation by tissue, 3) completion of therapy at one setting, and 4)
the opportunity at the time of implantation to stage the disease
accurately by bilateral pelvic lymphadenectomy. Indications for
radionuclide hrachytherapy (e.g., iodine-125 or palladium-103)
are usually comparable to those for a radical prostatectomy (i.e.,
patients with stage Bt or B2 with tow-grade histology). In recent years, substantial progress has been made to improve distribution of the radiation dose within the prostate using computed
tomography (CT) or transrectal ultrasound to guide implantation. These approaches are technically far superior to conven-

tional retropubic implantation (9-15). We have successfully
tteated several early stage prostate cancers with a perineal implantation technique using CT-based guidance.
Most patients with early stage prostatic cancers (i.e., stages
A2, B l , and B2 with high-grade histology) are excellent candidates for extemal beam radiation therapy. A high-energy external beam is essential to deliver the dose of radiation needed to
achieve tumor control and to minimize damage to the adjacent
normal tissue. Extemal beam treatment of prostate cancer must
involve a high-energy linear accelerator (usually more than 10
MeV x-rays), the use of simulation, and complex field anangements (usually four or more fields), as well as optimization in
the radiation dosimetry. CT scan and other imaging data are
used to achieve this optimized treatment plan (Figure). The
complex multiple field technique permits delivery of a curative
dose of radiation (65 to 70 Gy) to the prostate with a minimal
normal tissue morbidity.
The results of several large retrospective series (16-18) reporting extemal beam radiotherapy of the prostate cancer are
presented in Table 1. Survival rates for treated patients with
stage A disease at 5 and 10 years are 82%-95% and 70%-85%,
respectively. Of patients with stage B tumors, 75% survived 5
years and 40% to 55% survived 10 years. Through 15 years of
follow-up, overall survival in the patients treated surgically
(19,20) and those in stage B l treated with extemal beam radiotherapy (16) did not deviate significantly from each other (rates
of 51%, 57%, and 52%, respectively).
Perez et al (17) reported a 70% disease-specific 10-year survival rate for stage A2 and 55% for stage B disease. The 10-year
disease-specific rates in the pattems of care studies (PCS) in the
United States are comparable (77% for stage A and 40% for
stage B) (18).

Treatment of Locally Advanced Prostate
Cancer (Stage C, Dl, or T3-T4)
In all the series of prostate cancer presented to the National
Institutes of Health Consensus Development Conference (June
1987), the initial size or stage of the tumor at diagnosis was the
most significant factor in predicting the outcome (21). In patients who presented with a palpable tumor extending outside
the prostate (stages T3 and T4 or stage C), local recurrence rates

Table 1
Survival Results With External Beam Radiation Therapy
in Localized Disease (Stages A and B)
Overall (Actuarial) Survival (%)
5 years
10 years
15 years

Series
Bagshaw
et al(I6)
Perez etal (17)
Hantcs et al (18)
(POC)

A
Bl
B2
A2
i'.
A
B

95
80
80
79
76
83
73

75
6(1
55
67
?o
(-.2
46

45
.x5
33

Disease-Specific Survival (%)
5 years
10 years
15 years
95
85
85
82
75
84
fi6

85
75
65
7(1
55
77
4(1

85
64
45

POC = Patterns of care studies in the United Slates.

104

Henry Ford Hosp Med J—Vol 40. Nos 1 & 2. 1992

Therapeutic Options for Localized Prostate Cancer—Khil & Kim

were 25% to 40% and the probability of progression with distant
metastases was 50% to 75% (21). In contrast to the results
achieved from the management of stages A and B disease, lOyear survival after presentation with locally advanced prostate
cancer is a disappointing 20% to 40% (22-25). The tumor control rate by radiation therapy is inversely proportional to the size
of the tumor and higher doses are necessary for larger tumors
(26). External beam radiotherapy can be applied to periprostatic
extension of cancer that cannot be removed surgically (stage C).
Doses exceeding 7,000 cGy are necessary to minimize local recunences (27). A significant problem with these data is the inaccuracy of clinical staging without surgery; the local lesion may
be misstaged and the lymph nodes understaged in the absence of
lymphadenopathy.
Optimal management of locally advanced prostate cancer
with pelvic lymph node metastases (stage Dt or T4) is a therapeutic enigma. Regional lymph node involvement worsens the
prognosis, for the risk of distant spread in these patients is reportedly 75% to 80% (28). Accordingly, a broad range of treatments have been evaluated; early initiation of chemotherapy;
the combination of radiotherapy with hormonal manipulation;
and prostatectomy with interstitial inadiation. No prefened regimen has been defined, and detailed discussion of these modalities is beyond the scope of this review. Data conceming radiation efficacy in patients with lymph node involvement are
scarce However, Bagshaw (29) reported that 14% to 18% (depending on radiation portals) of patients survived for more than
5 years without evidence of cancer. In 1982 Paulson et al (30)
evaluated 41 patients with surgical stage D l disease who were
treated with extended field radiation alone. A total of 32% were
alive and disease-free at 60 months. Although recent data using
a mixed beam (neutron/photon) regimen for patients with locally advanced (stages C and Dl) carcinoma of the prostate have
shown superior results to standard photon therapy (locoregional
control at 5 years, 81% versus 60%), the study included a relatively small number of patients and the follow-up was relatively
short (31),
tn an effort to improve local tumor control and to increase the
survival rates of patients with locally advanced prostate cancer,
we devised a novel approach combining antimitotic chemotherapeutic agents and extemal beam radiation therapy. Based on
the growing understanding of the mechanism of action of antimitotic agents (e.g., estramustine phosphate and vinblastine sulfate), we initiated a pha.se tt study of concomitant administration
of estramustine and vinblastine in combination with extemal
beam radiation therapy. Radiobiological studies indicate that
cells accumulated in the G2 phase due to the drug-induced mitotic block would be highly sensitive to fractionated radiation
therapy, resulting in enhanced tumor cell kill. To date, the tolerance of patients to this regimen has been excellent.

Adjuvant Radiation Therapy
After Prostatectomy
for Pathologic Stage C Cancer
Postoperative radiotherapy has not been used so commonly
for cancer of the prostate as for other cancers but has been used
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Table 2
Postprostatectomy Radiation Therapy
Before Local Recurrence

Series
Rosen et al (32)
Gibbons et al (33)
Hanks & Dawson (34)
Ray et al (35)
Pilepich et al (36)
Total

Number of Ltxally Controlled/
Number of Patients

Five-Year
Survival (%)

15/16
21/22
10/10
10/13
18/18
74/79 (94%)

94
73
86
57
4.-S

in small groups of patients at several centers. For the most part,
this treatment has been utilized in patients after incomplete surgery or in those with pathologic stage C malignancy (surgical
margin positive in histological examination, microscopic invasion through the capsule or infiltration of the seminal vesicles),
tn these patients, local recurrence would be expected in 20% to
45% after surgery atone The locat control of prostate cancer
when adjuvant inadiation was given either before or after local
recunence is tabulated in Tables 2 and 3 (32-36). Control was
obtained in 94% of the patients treated shortly after surgery but
only in 70% of patients who were treated after clinical recurrence. From these data one can conclude that immediate radiotherapy improves the chance of cure after incomplete surgery.
However, there were no significant differences in survival between the inadiated and noninadiated pathologic stage C patients. Therefore, the Southwestem Oncology Group is conducting a prospective randomized study comparing observation versus postoperative radiation therapy for pathologic stage C prostate cancer.

Assessment of Local Control: Significance
of Post Radiotherapy Biopsy
In the majority of cases, cancer of the prostate is a slowly
growing tumor but simultaneously is a slowly regressing tumor.
Until there is better systemic management of prostate cancer, local control is the only realistic goal of local therapy, whether radiation treatment or surgery.
Avoiding the distressing symptoms which resutt from local
failure contributes to quality of life and is an important goal of

Table 3
Postprostatectomy Radiation Therapy
After Local Recurrence
Number of Locally Controlled/
Number of Patients

Series
Rosen et al(32)
Gibbons et al (33)
Hanks & Dawson (34)
Ray et al (35)
Total

10/13
16/23
8/10
11/19
45/65 (70%)

Five-Year
Survival (%)
15
40

71
40
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radiation therapy (37). Assessment of local results immediately
after radiotherapy may be misleading because it may require
many months after treatment to achieve complete regression.
Perez et at (38,39) found complete regression three months after
radiotherapy in 44% of stage B and 22% of stage C patients,
whereas the ultimate local control rates were 89% and 66%, respectively.
Cox and Kline (40) performed serial biopsies of the prostate
in patients with stage C disease after extemal beam radiation
therapy. The number of positive biopsies fell from 66% three to
six months after therapy to 19% two to three years later. They
found that after adequate inadiation, positive biopsies performed even one to two years later did not predict the ultimate
result. In contrast to this series, a study of prostate biopsies 6 to
36 months after completion of radiotherapy does show a conelation between posttive posttreatment biopsy and progressive
disease (41), If any biopsy was positive, 60% of the patients
eventually developed local recunence; with negative biopsies,
only 19% developed local recunence. This issue will not be resolved until a prospective trial is conducted. However, periodic
digital examination is considered adequate to evaluate local
control, and biopsy can be limited to those patients who have
clinical evidence of progression.

Prostate-Specific Antigen as
a New Tumor Marker
Prostate-specific antigen (PSA) is a useful tumor marker for
monitoring response to radiotherapy in patients with prostate
cancer. The test can identify patients at risk for failure, allowing
early intervention with hormone therapy or chemotherapy, PSA
is far superior to acid phosphatase in predicting treatment failure The decline in serum levels of PSA after "definitive" radiation for localized prostate cancer is much delayed when compared to the drop after surgical excision, but it is nonetheless
useful prognostically. In the Stanford .series serial values were
stable after one year in 49% ofthe patients but were increasing
in 51% (42,43), Relapse should be suspected if the PSA is not
normal within six months after completion of radiation therapy.
Future studies may further define the role of PSA as an indication of early relapse of prostate cancer.

Summary and Future Prospects
The efficacy of radiation therapy in the treatment of early
stages of prostate cancer has been well established. In cancers
limited to the prostate gland, results of radiotherapy are as good
as that of radical prostatectomy. Because of the comparable
long-term tumor control rates, patients with early stages of prostate cancer have various options for curative treatment. These
include radical prostatectomy, radionuclide hrachytherapy, and
extemal beam radiation therapy. Stage of the tumor, histologic
grade, size of the primary tumor, and overall medical conditions
of the patient must alt be considered in selecting a therapeutic
modality.
Considerable progress has been made in delivering high tumoricidal doses of radiation using extemal beam therapy.
Highly focused precision delivery of radiation is feasible he-
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cause of improved imaging techniques and complex multiple
field anangements. There has also been significant technical
progress in the use of hrachytherapy. Radioiodine-125 can be
implanted successfully in most patients with early stage, lowgrade prostate cancers utilizing a CT-guided transperineal approach.
For locally advanced stages of prostate cancer, a variety of
new technological and radiobiological approaches are being
evaluated at our institution. These include the use of a multileaf
collimated linear accelerator to deliver three-dimensional external beam radiotherapy. Evaluation of concomitant chemotherapy and radiotherapy is well under way for patients with localized prostatic cancer of high-grade histology. Other experimental modalities such as hyperthermia, photodynamic therapy, and
radiation chemical sensitizers may prove to be of value.
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